What is Curiox Biosystems?
Curiox Biosystems, a bioinstrumentation company originating from Singapore's Agency for Science, Technology, and Research (A*STAR), has established itself as a frontrunner in innovative assay platforms. Leveraging its deep expertise in surface chemistry and engineering, Curiox is dedicated to advancing life sciences, drug discovery, and diagnostics through the miniaturization and enhanced automation of bioassays. The company's strategic vision is centered on accelerating scientific breakthroughs by providing cutting-edge solutions.
How much funding has Curiox Biosystems raised?
Curiox Biosystems has raised a total of $33.2M across 3 funding rounds:
Series A
$3.2M
Series B
$15M
Series C
$15M
Series A (2010): $3.2M with participation from Zicom Group
Series B (2019): $15M led by HB Investment, IMM Investment, SV Investment, KB Investment, DAYLI Investment, and QUAD Investment
Series C (2022): $15M supported by Quad Investment Management, KB Investment, and Luha Private Equity
Key Investors in Curiox Biosystems
Quad Investment Management
Quad Investment Management is a significant backer, likely focusing on strategic growth opportunities within the technology and life sciences sectors.
KB Investment
KB Investment, a venture capital and private equity firm established in 1990 and headquartered in Seoul, South Korea, specializes in investing in innovative technology and entrepreneurial ventures.
Luha Private Equity
Luha Private Equity is an undisclosed investor participating in the funding round, suggesting a strategic interest in Curiox Biosystems' market potential.
What's next for Curiox Biosystems?
The recent major strategic investment signals a pivotal growth phase for Curiox Biosystems. This capital is expected to fuel further research and development, expand its commercialization efforts, and potentially broaden its market reach. The company's focus on automation and miniaturization in bioassays positions it to capitalize on the increasing demand for efficient and scalable solutions in the life sciences and pharmaceutical industries. Future developments will likely involve enhancing its existing assay platforms and exploring new applications for its proprietary technologies.
See full Curiox Biosystems company page
